DOCSLIB.ORG

R&D Pipeline – New Molecular Entities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
R&D Pipeline – New Molecular Entities Pipeline charts as communicated at (*) Q4 and Full Year 2019 Results R&D Pipeline – New Molecular Entities Meeting dated February 6, 2020 Phase 1 Phase 2 Phase 3 Registration (Total : 21) (Total : 7) (Total : 8) (Total : 2) SAR441344(**)(1) ST400(**)(5) SAR440340(**)(11) SAR422459(**)(13) avalglucosidase alfa Sarclisa® Anti-CD40L mAb Ex Vivo ZFN Gene-Edited Cell Anti-IL33 mAb ABCA4 gene therapy Neo GAA Anti-CD38 mAb Multiple Sclerosis Therapy, Beta thalassemia Atopic Dermatitis Stargardt Disease Pompe Disease 3L RRMM (ICARIA) (U.S.,EU) SAR439459 BIVV003(**)(5) romilkimab (SAR156597) SAR442168(**)(14) venglustat SAR341402 (insulin aspart) anti-TGFb mAb Ex Vivo ZFN Gene-Edited Cell Anti-IL4/IL13 bispecific mAb BTK inhibitor Oral GCS inhibitor Rapid acting insulin Advanced Solid Tumors Therapy, Sickle Cell Disease Systemic Scleroderma Multiple Sclerosis ADPKD(15) Type 1/2 Diabetes (EU) REGN5458(**)(2) olipudase alfa SAR439859 fitusiran O BIVV020 R R Anti-BCMAxCD3 bispecific mAb rhASM SERD RNAi targeting anti-thrombin Complement C1s inhibitor Relapsed Refractory MM ASMD(12) ad+ped Metastatic Breast Cancer 2/3L Hemophilia A and B O REGN4018(**)(2) SAR443060(**)(6) SAR339375 sutimlimab Anti-MUC16xCD3 bispecific mAb RIPK1 inhibitor(7) miRNA-21 Anti Complement C1s mAb Ovarian Cancer Amyotrophic Lateral Sclerosis Alport Syndrome Cold Agglutinin Disease SAR442720(**)(3) SAR443122(**)(6) BIVV001(**)(16) SHP2 inhibitor RIPK1 inhibitor(7) rFVIIIFc – vWF – XTEN(17) Solid Tumors Inflammatory indications Hemophilia A SAR440234 SAR441169(**)(8) nirsevimab(**)(18) T cell engaging multi specific mAb RORC (ROR gamma T) antagonist, Respiratory syncytial virus Leukemia Psoriasis Monoclonal Antibody SAR441000(**)(4) SAR441236 R Registrational Study (other than Phase 3) SAR408701 Cytokine mRNA Tri-specific neutralizing mAb Maytansin-loaded anti-CEACAM5 Solid tumors HIV O Opt-in rights products for which rights have not been exercised yet mAb, NSCLC 2/3L SAR442085 Next Gen PCV(**)(9) Immuno-inflammation MS & Neuro efpeglenatide(19) Anti CD38 mAb Fc engineered Pneumococcal Conjugate Oncology Diabetes Long-acting GLP-1 agonist Multiple Myeloma Vaccines Type 2 Diabetes Rare Diseases Cardiovascular & metabolism REGN5459(**)(2) O Herpes Simplex Virus Type 2(**)(10) Rare Blood Disorders Vaccines Anti-BCMAxCD3 bispecific mAb HSV-2 therapeutic vaccine Relapsed Refractory MM (1) Developed in collaboration with Immunext (14) Developed in collaboration with Principia (2) Regeneron product for which Sanofi has opt-in rights (15) Autosomal Dominant Polycystic Kidney Disease THOR-707 Respiratory syncytial virus (3) Developed in collaboration with Revolution Medicines (16) Developed in collaboration with Sobi (4) Developed in collaboration with BioNTech Non-alpha IL-2 Infants 4-month and older (17) Recombinant Coagulation Factor VIII Fc – von Willebrand Factor – XTEN Fusion protein (5) Developed in collaboration with Sangamo (18) Developed in collaboration with AstraZeneca Solid tumors Vaccines (6) Developed in collaboration with Denali (19) Developed in collaboration with Hamni – Sanofi has committed to complete ongoing studies (7) Receptor-interacting serine/threonine-protein kinase 1 – Sanofi is looking for a partner to take over and commercialize efpeglenatide (8) Developed in collaboration with Lead Pharma (*) Phase of projects determined by clinicaltrials.gov disclosure timing when relevant Yellow Fever (9) Developed in collaboration with SK Vaccine (Vero cell) (**) Partnered and/or in collaboration – Sanofi may have limited or (10) Developed in collaboration with Immune Design/Merck shared rights on some of these products (11) Developed in collaboration with Regeneron mAb = monoclonal antibody; RRMM = Relapsed Refractory Multiple Myeloma;; (12) Acid Sphingomyelinase Deficiency also known as Niemann Pick type B GCS = glucosylceramide synthase 2 (13) Identification of out-licensing partner ongoing Pipeline charts as communicated at (*) Q4 and Full Year 2019 Results Additional Indications Meeting dated February 6, 2020 Phase 1 Phase 2 Phase 3 Registration (Total : 7) (Total : 17) (Total : 26) (Total : 3) SAR439459 + cemiplimab(**)(1) dupilumab(**)(1) isatuximab + cemiplimab(**)(1) Dupixent®(**)(1) isatuximab Fluzone® QIV HD Advanced Solid Tumors Grass pollen allergy Relapsed Refractory MM Asthma 6 - 11 years old Newly Diag. MM Te(9) (GMMG) Influenza vaccine - High dose (EU) O cemiplimab(**)(1) + REGN4018(**)(2) R sarilumab(**)(1) isatuximab + cemiplimab(**)(1) dupilumab(**)(1) isatuximab MenQuadfiTM Ovarian Cancer Polyarticular Juvenile Idiopathic Arthritis Lymphoma Eosinophilic Esophagitis 2L RRMM (IKEMA) U.S. 2y+ , EU 1y+ SAR439859 + palbociclib(3) R sarilumab(**)(1) isatuximab + atezolizumab(7) Dupixent®(**)(1) isatuximab Dupixent®(**)(1) Metastatic Breast Cancer Systemic Juvenile Arthritis mCRC AD 6 months - 5 years old 1L Newly Diag. MM Ti(10) (IMROZ) AD 6 – 11 years old (U.S., EU) sutimlimab SAR440340(**)(1) isatuximab + atezolizumab(7) dupilumab(**)(1) Aubagio® Immune Thrombocytopenic Purpura COPD Solid Tumors COPD Relapsing MS – Pediatric SAR443060(**)(4) dupilumab(**)(1) venglustat dupilumab(**)(1) Lemtrada® Multiple sclerosis Peanut Allergy - Pediatric Fabry Disease Bullous pemphigoid Relapsing Remitting MS - Pediatric SAR442720(**)(5) + cobimetinib. SAR440340(**)(1) venglustat dupilumab(**)(1) Cerdelga® Relapsed Refractory solid tumors Asthma Gaucher Type 3 Chronic spontaneous urticaria Gaucher T1, ERT switch Pediatric SAR441000(**)(6) + PD-1 R cemiplimab(**)(1) venglustat dupilumab(**)(1) Praluent® (**)(1) Solid tumors 2-L Basal Cell Carcinoma GBA-PD(8) Prurigo nodularis LDL-C reduction - Pediatric isatuximab SP0173 sarilumab(**)(1) Praluent® (**)(1) 1-2L AML / ALL pediatrics Tdap booster US Giant Cell Arteritis LDL-C reduction – HoFH SAR439859 sarilumab(**)(1) MenQuadfiTM Breast Cancer adjuvant Polymyalgia Rheumatica 6w+ (US / EU) R Registrational study (other than Phase 3) cemiplimab(**)(1) Pediatric pentavalent vaccine(**)(11) Immuno-inflammation O Opt-in rights products for which rights have not been exercised yet 1L NSCLC Japan Oncology (1) Developed in collaboration with Regeneron (6) Developed in collaboration with BioNTech Rare Diseases cemiplimab(**)(1)+ chemotherapy Shan 6 (2) Regeneron product for which Sanofi has opt-in rights (7) Studies in collaboration with Genentech Inc. (atezolizumab) Rare Blood Disorders (3) Pfizer product (palbociclib) (8) Parkinson’s Disease with an associated GBA mutation 1L NSCLC Pediatric hexavalent vaccine (4) Developed in collaboration with Denali (9) Transplant eligible MS & Neuro (5) Developed in collaboration with Revolution Medicines - (10) Transplant ineligible cobimetinib is a Genentech product (11) Developed in collaboration with Kitasato and Daiichi Sankyo (KDSV) cemiplimab(**)(1) VerorabVax® (VRVg) Diabetes (*) Phase of projects determined by clinicaltrials.gov disclosure timing when relevant 2L Cervical Cancer Purified vero rabies vaccine (**) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products Cardiovascular & metabolism COPD = chronic obstructive pulmonary disease; AML = acute myeloïd leukemia; ALL = acute lymphoblastic leukemia; Vaccines MM = multiple myloma;; RRMS = Relapsing / Remitting Multiple Sclerosis cemiplimab(**)(1) fitusiran adjuvant in CSCC Hemophilia A and B pediatric 3 Pipeline charts as communicated at Q4 and Full Year 2019 Results Pipeline movements since Q3 2019 Meeting dated February 6, 2020 Additions / Moves Removals from Sanofi pipeline Dupixent®(**)(1 Registration AD 6 – 11 years old (U.S., EU) BIVV001(**)(2) rFVIIIFc – vWF – XTEN(3) Hemophilia A SAR408701 dupilumab(**)(1) Maytansin-loaded anti-CEACAM5 Phase 3 Chronic spontaneous urticaria mAb, NSCLC 2/3L dupilumab(**)(1) dupilumab(**)(1) Bullous pemphigoid Prurigo nodularis SAR439859 HIV SAR439859 SERD Viral vector prime & rgp120 boost Breast Cancer adjuvant Phase 2 Metastatic Breast Cancer 2./3L vaccine SAR441000(**)(4) + PD-1 Yellow Fever Solid tumors Vaccine (Vero cell) Phase 1 THOR-707 Non-alpha IL-2 Solid tumors (1) Developed in collaboration with Regeneron (2) Developed in collaboration with Sobi (3) Recombinant Coagulation Factor VIII Fc – von Willebrand Factor – XTEN Fusion protein (4) Developed in collaboration with BioNTech (**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products 5.
Load more

Recommended publications
  • (Human Papillomavirus 9-Valent Vaccine, Recombinant), for Use In
    tools Approved Drugs FDA has approved a supplemental new drug propelled, joystick-controlled, easy-to-use application (sNDA) for Xtandi® colonoscope system. • The Food and Drug Administration (FDA) (enzalutamide) capsules in advanced has approved a supplemental biologics prostate cancer. • Varian Medical Systems (varian.com) has license application (sBLA) for the use of received 510(k) clearance from the FDA to Arzerra® (ofatumumab) (Genmab A/S, market the Nexus DR, a high resolution genmab.com) in combination with Drugs in the News imaging system for X-ray imaging using a fludarabine and cyclophosphamide for the digital X-ray detector. treatment of patients with relapsed chronic • Genentech (gene.com) has received a lymphocytic leukemia (CLL). second breakthrough therapy designation Approved Genetic Tests & from the FDA for Alecensa® (alectinib) Assays • Amgen (amgen.com) announced that the for the treatment of adult patients with FDA has approved the sBLA for Blincyto® advanced ALK-positive NSCLC who have • AstraZeneca (astrazeneca-us.com) (blinatumomab) to include new data not received prior treatment with an ALK announced that the FDA has approved a supporting the treatment of pediatric patients inhibitor. blood-based companion diagnostic for with Philadelphia chromosome-negative (Ph-) Tagrisso® (osimertinib). relapsed or refractory B-cell precursor acute • AbbVie (abbvie.com) submitted an sNDA lymphoblastic leukemia (ALL). to the FDA for Imbruvica® (ibrutinib) to treat patients with marginal zone lymphoma, • Merck Sharp & Dohme Corp.’s (merck.com) a form of non-Hodgkin’s lymphoma. FDA Approves Two-Dose Keytruda® (pembrolizumab) has received Vaccination Regime FDA approval in first-line non-small cell lung • Fate Therapeutics, Inc.
    [Show full text]
  • Study Protocol
    Official Title: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL CANCER (MODUL) NCT Number: NCT02291289 Document Date: Protocol Version 9: 18-Feb-2020 PROTOCOL TITLE: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL) PROTOCOL NUMBER: MO29112 VERSION NUMBER: 9 EUDRACT NUMBER: 2014-001017-61 IND NUMBER: N/A TEST PRODUCT: Atezolizumab (MPDL3280A, RO5541267) Bevacizumab (RO4876646) Cobimetinib (RO5514041) Pertuzumab (RO4368451) Trastuzumab (RO0452317) Vemurafenib (RO5185426) Cetuximab And combinations thereof MEDICAL MONITOR: Dr. SPONSOR: F. Hoffmann-La Roche Ltd. DATE FINAL: See electronic date stamp below FINAL PROTOCOL APPROVAL Date and Time (UTC) Title Approver's Name 18-Feb-2020 15:44:34 Company Signatory CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. Bevacizumab — F. Hoffmann-La Roche Ltd. Protocol MO29112, Version 9 DATES AMENDED: Version 1: 5 August 2014 Version 2: 29 October 2014 Version 3: 2 February 2015 Version 4: 30 November 2015 Version 5: 11 April 2016 Version 6: 24 November 2016 Version 7: 8 August 2018 Version 8: 19 December 2018 Bevacizumab — F.
    [Show full text]
  • Combinations of Immunotherapy and Radiation Therapy in Head and Neck Squamous Cell Carcinoma: a Narrative Review
    2585 Review Article on Synergy in Action: Novel Approaches to Combining Radiation Therapy and Immunotherapy Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review Thomas J. Hayman1, Aarti K. Bhatia2, Krishan R. Jethwa1, Melissa R. Young1, Henry S. Park1^ 1Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA; 2Section of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT, USA Contributions: (I) Conception and design: TJ Hayman, HS Park; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: TJ Hayman, HS Park; (V) Data analysis and interpretation: TJ Hayman, HS Park; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Henry S. Park, MD, MPH. Assistant Professor of Therapeutic Radiology, Yale School of Medicine, 35 Park Street, Lower Level, New Haven, CT 06520, USA. Email: [email protected]. Abstract: Radiation therapy and systemic therapy are the primary non-surgical treatment modalities for head and neck squamous cell carcinoma (HNSCC). Despite advances in our biologic understanding of this disease and the development of novel therapeutics, treatment resistance remains a significant problem. It has become increasingly evident that the innate and adaptive immune systems play a significant role in the modulation of anti-tumor responses to traditional cancer-directed therapies. By inducing DNA damage and cell death, radiation therapy appears to activate both innate and adaptive immune responses. Immunotherapies targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) also have yielded promising results, particularly in the recurrent/metastatic setting.
    [Show full text]
  • TECENTRIQ® (Atezolizumab) Injection, for Intravenous Use DOSAGE FORMS and STRENGTHS Initial U.S
    of 4-6 cycles. Following completion of chemotherapy, TECENTRIQ 1200 HIGHLIGHTS OF PRESCRIBING INFORMATION mg IV, following by bevacizumab, every 3 weeks. These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for If the first infusion is tolerated, all subsequent infusions may be delivered over TECENTRIQ. 30 minutes. (2.2, 2.3) TECENTRIQ® (atezolizumab) injection, for intravenous use DOSAGE FORMS AND STRENGTHS Initial U.S. Approval: 2016 Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial (3) RECENT MAJOR CHANGES CONTRAINDICATIONS Indications and Usage, Urothelial Carcinoma (1.1) 7/2018 None. (4) Indications and Usage, Non-Small Cell Lung Cancer (1.2) 12/2018 Dosage and Administration (2.3) 7/2018 WARNINGS AND PRECAUTIONS Warnings and Precautions, Pneumonitis (5.1) 12/2018 Immune-Mediated Pneumonitis: Withhold or permanently discontinue Warnings and Precautions, Hepatitis (5.2) 12/2018 based on severity of pneumonitis. (2.4, 5.1) Warnings and Precautions, Colitis (5.3) 12/2018 Immune-Mediated Hepatitis: Monitor for changes in liver function. Warnings and Precautions, Endocrinopathies (5.4) 12/2018 Withhold or permanently discontinue based on severity of transaminase or Warnings and Precautions, Infections (5.6) 12/2018 total bilirubin elevation. (2.4, 5.2) Warnings and Precautions, Infusion-Related Reactions (5.7) 12/2018 Immune-Mediated Colitis: Withhold or permanently discontinue based on severity of colitis. (2.4, 5.3) INDICATIONS AND USAGE Immune-Mediated Endocrinopathies (2.4, 5.4): TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody o Hypophysitis: Withhold based on severity of hypophysitis.
    [Show full text]
  • Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma
    Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma Company Announcement Phase Ib studies of daratumumab in combination with Roche’s immune checkpoint inhibitor atezolizumab in a solid tumor and multiple myeloma to be started Studies conducted under a clinical trial collaboration agreement between Janssen and Roche Copenhagen, Denmark; March 21, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that daratumumab will be investigated in early stage clinical studies in combination with atezolizumab (anti-PD-L1 antibody), in a solid tumor and multiple myeloma. The studies will be conducted under a clinical trial collaboration agreement between Genmab’s licensing partner for daratumumab, Janssen Biotech, Inc., and Genentech, a member of the Roche Group. Atezolizumab is an investigational monoclonal antibody designed to bind to a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells. Janssen will conduct a Phase Ib study of daratumumab in combination with atezolizumab to treat a solid tumor. Genentech will amend an ongoing Phase Ib study to assess atezolizumab in combination with daratumumab, with daratumumab and lenalidomide, and with daratumumab and pomalidomide in relapsed/refractory multiple myeloma (NCT02431208). The studies are expected to start enrolling patients later this year and information about the studies will be posted on www.clinicaltrials.gov. “We are very excited about the start of the first study to investigate daratumumab in a solid tumor, potentially expanding its clinical utility beyond hematological cancers. We are equally excited about testing daratumumab in combination with an immune checkpoint inhibitor, such as Roche’s anti-PDL1, atezolizumab, in multiple myeloma.
    [Show full text]
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • A Phase Ib/II Study Evaluating the Safety and Efficacy Of
    Official Title: A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT Number: NCT02729896 Document Date: Protocol Version 8: 07-November-2018 PROTOCOL TITLE: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PROTOCOL NUMBER: BO29561 VERSION NUMBER: 8 EUDRACT NUMBER: 2015-004845-25 IND NUMBER: 128036 TEST PRODUCT: Obinutuzumab (RO5072759) Rituximab (RO0452294) Atezolizumab (RO5541267) Polatuzumab vedotin (RO5541077) MEDICAL MONITOR: , Ph.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 12 November 2015 DATES AMENDED: Version 2: 14 January 2016 Version 3: 28 June 2016 Version 4: 17 November 2016 Version 5: 4 May 2017 Version 6: 21 December 2017 Version 7: 1 May 2018 Version 8: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 07-Nov-2018 02:00:10 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F.
    [Show full text]
  • Study Protocol
    Official Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study Of The Efficacy And Safety Of Trastuzumab Emtansine In Combination With Atezolizumab Or Atezolizumab- Placebo In Patients With HER2-Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab And Taxane Based Therapy NCT Number: NCT02924883 Document Date: Protocol Version 3: 09 Aug 2017 PROTOCOL TITLE: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY PROTOCOL NUMBER: WO30085 VERSION NUMBER: 3 EUDRACT NUMBER: 2015-004189-27 IND NUMBER: 71,072 TEST PRODUCT: Trastuzumab Emtansine (RO5304020) Atezolizumab (RO5541267) MEDICAL MONITOR: , M.D. , Ph.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 14 April 2016 DATE AMENDED: Version 2: 21 December 2016 Version 3: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 09-Aug-2017 16:54:13 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board.
    [Show full text]
  • Cyramza® (Ramucirumab)
    Cyramza® (ramucirumab) (Intravenous) -E- Document Number: MODA-0405 Last Review Date: 07/01/2021 Date of Origin: 09/03/2019 Dates Reviewed: 09/2019, 10/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 07/2021 I. Length of Authorization Coverage will be provided for 6 months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Cyramza 100 mg/10 mL: 4 vials per 14 days • Cyramza 500 mg/50 mL: 2 vials per 14 days B. Max Units (per dose and over time) [HCPCS Unit]: Gastric, Gastroesophageal, HCC, and Colorectal Cancer: • 180 billable units every 14 days NSCLC: • 240 billable units every 14 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND Universal Criteria 1 • Patient does not have uncontrolled severe hypertension; AND • Patient must not have had a surgical procedure within the preceding 28 days or have a surgical wound that has not fully healed; AND Gastric, Esophageal, and Gastro-esophageal Junction Adenocarcinoma † Ф 1-3,5-7,14,17,2e,5e • Used as subsequent therapy after fluoropyrimidine- or platinum-containing chemotherapy; AND • Used as a single agent OR in combination with paclitaxel; AND o Used for one of the following: Moda Health Plan, Inc. Medical Necessity Criteria Page 1/27 Proprietary & Confidential © 2021 Magellan Health, Inc. – Patient has unresectable locally advanced, recurrent, or metastatic disease; OR – Used as palliative therapy for locoregional disease in patients who are not surgical candidates
    [Show full text]
  • 1 Oncologic Drugs Advisory Committee (ODAC)
    Oncologic Drugs Advisory Committee (ODAC) Meeting April, 27, 2021 BLA# 761034/Supplement 18 Drug name: TECENTRIQ® (atezolizumab) Applicant: Genentech, Inc. Combined FDA and Applicant ODAC Briefing Document Advisory Committee Briefing Materials: Available For Public Release 1 DISCLAIMER STATEMENT The attached package contains background information prepared by the Applicant and the Food and Drug Administration (FDA) for the panel members of the advisory committee. The package contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the drug TECENTRIQ® (also known as atezolizumab) to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting. 2 Table of Contents Table of Tables .........................................................................................................................
    [Show full text]
  • FDA Updates Highlighting the Latest Cancer Treatments
    FDA Updates Highlighting the Latest Cancer Treatments Orphan Drug Designation of NUV-422 for (mCRC) or squamous cell carcinoma of the head and neck (SCCHN). Malignant Gliomas This approval provides for a biweekly dosage regimen option in The FDA has granted Orphan Drug Designation to NUV-422, a cyclin- addition to the previously approved weekly dosage regimen for the dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of patients approved indications when cetuximab is used as a single agent or in with malignant gliomas. combination with chemotherapy. Patient enrollment and dosing is ongoing in the Phase I/II study The approval was based on population pharmacokinetic (PK) of NUV-422 in adult patients with recurrent or refractory high-grade modeling analyses that compared the predicted exposures of cetux- gliomas, including glioblastoma multiforme. The Phase I dose-esca- imab 500 mg Q2W to observed cetuximab exposures in patients who lation part of the study is designed to evaluate safety and tolerability, received cetuximab 250 mg weekly. The application was also supported as well as determine a recommended Phase II dose based on the toler- by pooled analyses of overall response rates, progression-free survival, ability profile and pharmacokinetic properties of NUV-422. The Phase and overall survival (OS) from published literature in patients with II dose expansion part of the study is expected to initially focus on CRC and SCCHN, and OS analyses using real-world data in patients patients with high-grade gliomas, and it is designed to evaluate overall with mCRC who received either the weekly cetuximab or Q2W regi- response rate, duration of response, and survival.
    [Show full text]
  • New Drug Updates Brendan Mangan, Pharmd Clinical Pharmacy Specialist Hospital of the University of Pennsylvania
    11/9/2020 Disclosures • There are no relevant financial interests to disclose for myself or my spouse/partner from within the last 12 months New Drug Updates Brendan Mangan, PharmD Clinical Pharmacy Specialist Hospital of the University of Pennsylvania 1 2 Objectives New Drugs Explain the pharmacology of each new medication Malignant Hematology Medical Oncology Define indications, adverse effects and pertinent drug interactions Outline supportive care measures and clinical pearls Selinexor Tazemotostat Isatuximab-irfc Avapritinib Discuss the results of clinical trials and place in therapy Belantamab mafodotin-blmf Pexidartinib Fedratinib Entrectinib Polatuzumab vedotin-piiq Tafasitamab-cxix Zanubrutinib 3 4 Selinexor (XPOVIO®) Approval: July 3, 2019 Novel agent Exportin 1 inhibitor ▫ Reversibly inhibits nuclear export of tumor suppressor proteins, growth regulators, and mRNAs of oncogenic proteins XPOVI™ [Prescribing Information] Newton, MA. Karyopharm Therapeutics. 2019. Picture: xpovio.com 5 6 1 11/9/2020 Selinexor Selinexor Indication Adverse Effects Clinical Pearls • In combination with dexamethasone for relapse refractory multiple myeloma after failing 4 prior therapies Thrombocytopenia (74%) GCSF and prophylactic antimicrobials Recommended Neutropenia (34%) Prophylactic anti-emetics First Reduction Second Reduction Third Reduction Starting Dosage Nausea (72%)/Vomiting (41%) IV fluids and electrolyte repletion may be Diarrhea (44%) warranted monitor closely 80 mg Discontinue Days 1 and 3 of each Anorexia (53%)/Weight loss (47%) Correct sodium levels for concurrent 100 mg once weekly 80 mg once weekly 60 mg once weekly week (160 mg weekly Hyponatremia (39%) hyperglycemia (>150 mg/dL) total) Infections (52%) TPO agonist may be warranted for Neurological toxicity (30%) thrombocytopenia GCSF = Granulocyte colony-stimulating factor XPOVI™ [Prescribing Information] Newton, MA.
    [Show full text]